Letter: Biochemical response to combination anti-retroviral therapy in patients with primary biliary cirrhosis

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 2, 2014, Pages 236-237

  Mason, A L ^a   Montano Loza, A J ^a   Saxinger, L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; OBETICHOLIC ACID; PLACEBO; URSODEOXYCHOLIC ACID;

CHEMICAL ANALYSIS; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME BLOOD LEVEL; EPITHELIUM CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LETTER; MAINTENANCE THERAPY; NONHUMAN; PILOT STUDY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROVIRUS; SURVIVAL PREDICTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DNA CELL DNA INTERACTION; VIRUS INFECTION; VIRUS ISOLATION;

CHOLAGOGUES AND CHOLERETICS; FEMALE; HUMANS; LIVER CIRRHOSIS, BILIARY; MALE; URSODEOXYCHOLIC ACID;

EID: 84890508877     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12575     Document Type: Letter

References (10)

1. Papastergiou V, Tsochatzis EA, Rodriquez-Peralvarez M, et al,. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther 2013; 38: 1354-64.
2. Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ,. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010; 52: 349-59.
3. Lammers WJ, van Buuren HR, Janssen HL, et al,. Validation of alkaline phosphatase and bilirubin values as a surrogate endpoint in primary biliary cirrhosis an International, Collaborative Study. Hepatology 2013; 58 (4 Suppl.): 250A.
4. Wang W, Indik S, Wasilenko S, Carpenter E, Wong G, Mason A,. Demonstration of human betaretrovirus integration in the genome of patients with primary biliary cirrhosis. Hepatology 2013; 58 (4 Suppl): 786A.
5. Xu L, Shen Z, Guo L, et al,. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci of the USA 2003; 100: 8454-9.
6. Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM, Wasilenko ST,. Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; 28: 886-94.
7. Mason A, Luketic V, Lindor K, et al,. Farnesoid-X Receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (INT-747) to ursodeoxycholic acid. Hepatology 2010; 52 (4 Suppl.): 357A.
8. Mason AL,. The evidence supports a viral aetiology for primary biliary cirrhosis. J Hepatol 2011; 54: 1312-4.
9. Schembri G, Schober P,. Killing two birds with one stone. Lancet 2011; 377: 96.
10. Randomized controlled trial: Pilot study of highly active antiretroviral therapy for patients with primary biliary cirrhosis. Available at: http://clinicaltrials.gov/ct2/show/NCT01614405.